MitoAction’s mission is to improve the quality of life for children, adults, and families living with mitochondrial disease through support, education, outreach, advocacy, clinical research initiatives and by granting wishes for children affected by mitochondrial disease.
To do this, MitoAction’s goals include:
*To improve quality of life for adults and children affected by mitochondrial disease.
*To internationally raise awareness about mitochondrial disorders, and their relationship to other diseases.
*To provide specific and practical materials that help patients to manage their symptoms
*To aggregate and connect the international mitochondrial disease community
*To engage pharmaceutical industry working toward therapeutic approaches to mitochondrial disorders.
*To create tools which empower patients and caregivers to be advocates for themselves or their children.
*To create unique experiential opportunities for adults and children affected by mitochondrial disease.
We strive to offer comprehensive, up-to-date, expert resources, information, and support at no cost to any patient, family, clinician, educator, or member of the community.
We continue to seek multiple ways to offer information such that the resources are accessible and user-friendly for people of all abilities.
We foster relationships with the scientific, academic, research and business community in order to create sustainable support for the mission of MitoAction.
Overview
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 16, 2025 | Leading Clinicians and Researchers Urge FDA to Reconsider Path Forward for DCA in Pyruvate Dehydrogenase Complex Deficiency | Leading advocacy groups and more than 80 scientific and medical leaders call on FDA to act urgently on DCA approval for PDCD, a rare and life-threatening mitochondrial disease WASHINGTON, Oct. 16, 2025 /PRNewswire-PRWeb/ -- In response to t... |
| Feb 4, 2022 | TK2d Patient Voices Elevated at FDA; United Mitochondrial Disease Foundation, MitoAction Champion First Ever Listening Session for this Rare Disease | PITTSBURGH (PRWEB) February 04, 2022 Today, the United Mitochondrial Disease Foundation (UMDF) and MitoAction shared reactions from the historic dialogue held during a listening session with the U.S. Food and Drug Administration (FDA) regar... |
Reviews 0
FAQ about MitoAction
When was MitoAction founded?
MitoAction was founded in 2005.
What has the press written about MitoAction?
Parsers VC has collected 3 articles mentioning MitoAction, among them “Leading Clinicians and Researchers Urge FDA to Reconsider Path Forward for DCA in Pyruvate Dehydrogenase Complex Deficiency” (Oct 16, 2025) and “TK2d Patient Voices Elevated at FDA; United Mitochondrial Disease Foundation, MitoAction Champion First Ever Listening Session for this Rare Disease” (Feb 4, 2022).
Is MitoAction still active?
Yes, MitoAction is active; its latest activity on Parsers VC dates from Oct 20, 2026.